Eli Lilly will release its third-quarter financial results on Thursday, with analysts projecting earnings per share of $6.26. Performance is anticipated to be anchored by Mounjaro and Zepbound, alongside early contributions from its newly launched obesity pill Foundayo. Even while navigating lower net prices in the United States, the drugmaker continues to outpace Novo in core markets. The company is actively reinvesting its windfalls into strategic acquisitions, including a psychedelics firm and three vaccine manufacturers.
Key points
Robust demand for Mounjaro and Zepbound continues to drive Eli Lilly's market lead over r…: Robust demand for Mounjaro and Zepbound continues to drive Eli Lilly's market lead over rival Novo.
The successful rollout of Foundayo marks an important expansion in the company's obesity…: The successful rollout of Foundayo marks an important expansion in the company's obesity treatment portfolio.
Substantial profits are enabling the drugmaker to diversify beyond metabolic treatments t…: Substantial profits are enabling the drugmaker to diversify beyond metabolic treatments through strategic acquisitions.
Sources checked by our analysis pipeline: 1
Eli Lilly is slated to report third-quarter earnings and revenue on Thursday, which will likely be fueled by its blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro.
Here's what Wall Street is expecting, based on a survey of analysts by LSEG:
- Earnings per share: $6.26 expected
- Revenue: $22.61 billion expected
But investors will also be laser-focused on the launch of the company's obesity pill, Foundayo, which entered the market in April. Analysts forecast around $229 million in sales for the pill, StreetAccount estimates showed.
Lilly's massive diabetes and obesity windfall – and dominance over chief rival Novo – show no signs of slowing down, even as the company grapples with lower net prices in the U.S. The pharma giant is converting these historic profits into a major dealmaking spree, striking a deal to buy a psychedelics drugmaker in July and announcing plans to purchase three vaccine makers in May.
Gallup's latest workplace assessment reveals that shrinking involvement was concentrated among off-site personnel, particularly within companies utilizing artificial intelligence tools. Declining sentiment directly threatens operational output and retention, as most historical progress toward the 2020 high-water mark of 36% has now disappeared. However, mixed labor signals like near-record broad satisfaction metrics suggest broader market dynamics remain fragmented.
Municipal officials in Rowlett are using eminent domain to expand Chiesa Road into a four-lane divided corridor to handle growing traffic volumes. The planned project requires demolishing the longtime residence of the Willis family and bisecting their property. The homeowners argue the city's payout fails to capture the true value created by nearby development.
Leadership updated financial guidance for the mid-decade horizon to reflect shifting operational expectations. While the drugmaker now anticipates stronger overall sales volume by 2026, bottom-line profitability will take a hit. An unforeseen financial charge is depressing net per-share returns despite the improved top-line momentum.